Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing Non-small Cell Lung Cancer”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Early research (Phase 1)Active Not RecruitingNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Early research (Phase 1)Looking for participantsNCT07334119
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-Expressing Solid Tumors
Myeloid Therapeutics 60
Early research (Phase 1)Not Yet RecruitingNCT07036185
What this trial is testing

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Who this might be right for
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal Cancer+3 more
Shanghai Bao Pharmaceuticals Co., Ltd. 66
Early research (Phase 1)Study completedNCT02952729
What this trial is testing

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

Who this might be right for
Advanced Breast CancerAdvanced Nonsmall Cell Lung CancerAdvanced Gastric Cancer
Mersana Therapeutics 120
Early research (Phase 1)Study completedNCT00228358
What this trial is testing

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung Cancer+6 more
University of Washington 8
Early research (Phase 1)Study completedNCT00005023
What this trial is testing

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Who this might be right for
Breast CancerLung CancerOvarian Cancer
University of Washington
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Early research (Phase 1)Study completedNCT00003002
What this trial is testing

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Who this might be right for
Breast CancerLung CancerOvarian Cancer
University of Washington 60
Testing effectiveness (Phase 2)Looking for participantsNCT06695845
What this trial is testing

Zanidatamab in Patients With HER2-expressing Tumors

Who this might be right for
Breast CancerGastric CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals 200
Early research (Phase 1)Study completedNCT04319757
What this trial is testing

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Locally Advanced Solid TumorMetastatic CancerSolid Tumor+2 more
Acepodia Biotech, Inc. 12
Early research (Phase 1)Looking for participantsNCT05969041
What this trial is testing

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Who this might be right for
Epithelial Tumors, Malignant
Myeloid Therapeutics 48
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Early research (Phase 1)Study completedNCT02892123
What this trial is testing

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Who this might be right for
HER2-expressing Cancers
Jazz Pharmaceuticals 279